SG11201509992RA - Dual selective pi3 delta and gamma kinase inhibitors - Google Patents
Dual selective pi3 delta and gamma kinase inhibitorsInfo
- Publication number
- SG11201509992RA SG11201509992RA SG11201509992RA SG11201509992RA SG11201509992RA SG 11201509992R A SG11201509992R A SG 11201509992RA SG 11201509992R A SG11201509992R A SG 11201509992RA SG 11201509992R A SG11201509992R A SG 11201509992RA SG 11201509992R A SG11201509992R A SG 11201509992RA
- Authority
- SG
- Singapore
- Prior art keywords
- delta
- kinase inhibitors
- dual selective
- gamma kinase
- gamma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2501CH2013 | 2013-06-07 | ||
| IN5567CH2013 | 2013-12-03 | ||
| PCT/IB2014/061954 WO2014195888A1 (en) | 2013-06-07 | 2014-06-04 | Dual selective pi3 delta and gamma kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509992RA true SG11201509992RA (en) | 2016-01-28 |
Family
ID=50980341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509992RA SG11201509992RA (en) | 2013-06-07 | 2014-06-04 | Dual selective pi3 delta and gamma kinase inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9790224B2 (en) |
| EP (1) | EP3004106B1 (en) |
| JP (1) | JP6499165B2 (en) |
| KR (1) | KR102292853B1 (en) |
| CN (1) | CN105358560B (en) |
| AP (1) | AP2015008888A0 (en) |
| AR (1) | AR096543A1 (en) |
| AU (1) | AU2014276476B2 (en) |
| BR (1) | BR112015030385B1 (en) |
| CA (1) | CA2913226C (en) |
| CL (1) | CL2015003562A1 (en) |
| CY (1) | CY1119615T1 (en) |
| DK (1) | DK3004106T3 (en) |
| EA (1) | EA029017B1 (en) |
| ES (1) | ES2648094T3 (en) |
| HK (1) | HK1217949A1 (en) |
| HR (1) | HRP20171795T1 (en) |
| HU (1) | HUE035237T2 (en) |
| IL (1) | IL242761B (en) |
| LT (1) | LT3004106T (en) |
| MX (1) | MX366449B (en) |
| NO (1) | NO3004106T3 (en) |
| PH (1) | PH12015502698A1 (en) |
| PL (1) | PL3004106T3 (en) |
| PT (1) | PT3004106T (en) |
| RS (1) | RS56606B1 (en) |
| SG (1) | SG11201509992RA (en) |
| SI (1) | SI3004106T1 (en) |
| TW (1) | TWI615144B (en) |
| WO (1) | WO2014195888A1 (en) |
| ZA (1) | ZA201508708B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004501A (en) | 2010-06-03 | 2021-11-09 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk). |
| BR112015001690A2 (en) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutations associated with resistance to bruton tyrosine kinase inhibitors (btk) |
| JP6501270B2 (en) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | Targeting agent-antibody conjugates and uses thereof |
| PL3003038T3 (en) | 2013-06-07 | 2020-02-28 | The Scripps Research Institute | 2h-1,2,3-triazole derivatives as inhibitors of fibrosis |
| CA2913226C (en) * | 2013-06-07 | 2023-01-03 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| JP6706023B2 (en) | 2014-12-10 | 2020-06-03 | ザ・スクリップス・リサーチ・インスティテュート | Small molecule inhibitors of fibrosis |
| BR112017013580A2 (en) * | 2014-12-23 | 2018-04-10 | Pharmacyclics Llc | btk inhibitor combinations and dosage regimen. |
| JP2021505571A (en) | 2017-12-06 | 2021-02-18 | ルヒゼン ファーマスティカルズ エスエー | Compositions and Methods for Treating Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma |
| EP4149629A1 (en) | 2020-05-14 | 2023-03-22 | Rhizen Pharmaceuticals AG | Purine derivatives as sik-3 inhibitors |
| WO2023125418A1 (en) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | Benzenesulfonic acid salt crystals and preparation method therefor |
| WO2023123742A1 (en) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | SEMI-FUMARATE CRYSTAL OF PI3Kδ/γ DUAL INHIBITOR COMPOUND, AND PREPARATION METHOD THEREFOR |
| WO2023125419A1 (en) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | Adipate crystal and preparation method therefor |
| WO2023130334A1 (en) * | 2022-01-07 | 2023-07-13 | 同润生物医药(上海)有限公司 | Method for preparing chromen-4-one compound and intermediate thereof |
| WO2023209634A1 (en) | 2022-04-29 | 2023-11-02 | Rhizen Pharmaceuticals Ag | A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2779574C (en) * | 2009-11-05 | 2018-12-18 | Rhizen Pharmaceuticals S.A. | Novel kinase modulators |
| TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| MX365160B (en) | 2011-05-04 | 2019-05-24 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinases. |
| CA2871000C (en) | 2012-05-04 | 2021-10-19 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
| CA2913226C (en) * | 2013-06-07 | 2023-01-03 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| JP2021505571A (en) * | 2017-12-06 | 2021-02-18 | ルヒゼン ファーマスティカルズ エスエー | Compositions and Methods for Treating Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma |
-
2014
- 2014-06-04 CA CA2913226A patent/CA2913226C/en active Active
- 2014-06-04 HU HUE14732019A patent/HUE035237T2/en unknown
- 2014-06-04 RS RS20171183A patent/RS56606B1/en unknown
- 2014-06-04 AU AU2014276476A patent/AU2014276476B2/en active Active
- 2014-06-04 ES ES14732019.6T patent/ES2648094T3/en active Active
- 2014-06-04 JP JP2016517722A patent/JP6499165B2/en active Active
- 2014-06-04 EA EA201592113A patent/EA029017B1/en unknown
- 2014-06-04 SI SI201430486T patent/SI3004106T1/en unknown
- 2014-06-04 PT PT147320196T patent/PT3004106T/en unknown
- 2014-06-04 WO PCT/IB2014/061954 patent/WO2014195888A1/en active Application Filing
- 2014-06-04 MX MX2015016741A patent/MX366449B/en active IP Right Grant
- 2014-06-04 US US14/295,875 patent/US9790224B2/en active Active
- 2014-06-04 CN CN201480032576.4A patent/CN105358560B/en active Active
- 2014-06-04 PL PL14732019T patent/PL3004106T3/en unknown
- 2014-06-04 KR KR1020167000160A patent/KR102292853B1/en active IP Right Grant
- 2014-06-04 EP EP14732019.6A patent/EP3004106B1/en active Active
- 2014-06-04 SG SG11201509992RA patent/SG11201509992RA/en unknown
- 2014-06-04 NO NO14732019A patent/NO3004106T3/no unknown
- 2014-06-04 BR BR112015030385-4A patent/BR112015030385B1/en active IP Right Grant
- 2014-06-04 DK DK14732019.6T patent/DK3004106T3/en active
- 2014-06-04 AP AP2015008888A patent/AP2015008888A0/en unknown
- 2014-06-04 LT LTEP14732019.6T patent/LT3004106T/en unknown
- 2014-06-06 TW TW103119720A patent/TWI615144B/en active
- 2014-06-06 AR ARP140102206A patent/AR096543A1/en not_active Application Discontinuation
-
2015
- 2015-11-24 IL IL242761A patent/IL242761B/en active IP Right Grant
- 2015-11-26 ZA ZA2015/08708A patent/ZA201508708B/en unknown
- 2015-12-03 PH PH12015502698A patent/PH12015502698A1/en unknown
- 2015-12-04 CL CL2015003562A patent/CL2015003562A1/en unknown
-
2016
- 2016-05-25 HK HK16105982.1A patent/HK1217949A1/en unknown
-
2017
- 2017-08-08 US US15/672,061 patent/US10851107B2/en active Active
- 2017-11-20 HR HRP20171795TT patent/HRP20171795T1/en unknown
- 2017-11-21 CY CY20171101216T patent/CY1119615T1/en unknown
-
2020
- 2020-05-01 US US16/865,034 patent/US11466006B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217949A1 (en) | Dual selective pi3 delta and gamma kinase inhibitors pi3 | |
| IL267681A (en) | Selective grp94 inhibitors and uses thereof | |
| HK1223089A1 (en) | Kinase inhibitor and use thereof | |
| HK1217198A1 (en) | Protein kinase inhibitors | |
| HK1220459A1 (en) | Kinase inhibitors | |
| IL238564B (en) | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor | |
| HK1219421A1 (en) | Combination of kinase inhibitors and uses thereof | |
| HK1219104A1 (en) | Kinase inhibitors | |
| HK1219057A1 (en) | Macrocyclic salt-inducible kinase inhibitors | |
| EP2986611A4 (en) | Certain protein kinase inhibitors | |
| EP2964225A4 (en) | CaMKII INHIBITORS AND USES THEREOF | |
| PT3150256T (en) | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201304083D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201304086D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201304084D0 (en) | Selective glycosidase inhibitors and uses thereof |